Navigation Links
MINRAD International, Inc. to Discuss 2008 First Quarter Financial Results on Tuesday, May 13, 2008

ORCHARD PARK, N.Y., May 8 /PRNewswire-FirstCall/-- MINRAD International, Inc. (Amex: BUF) announced today that the Company will hold an investor conference call to discuss first quarter 2008 financial results on Tuesday, May 13, 2008 at 4:30 PM ET. The Company will release first quarter 2008 results prior to the call on Tuesday, May 13, 2008.

The toll free call in number in the United States is (866) 866-1333. The international call in number is (404) 260-1421.

Contact: Charles R. Trego, Jr., Chief Financial Officer

(716) 855-1068

About the Company

MINRAD International, Inc. is an interventional pain management company with real-time image guidance and anesthesia and analgesia product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company's website,

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, Minrad International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of Minrad International's Form 10-KSB/A, filed with the Securities and Exchange Commission on April 21, 2008. Although Minrad International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.

SOURCE MINRAD International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MINRAD International, Inc. Announces $40.0 Million Private Placement
2. MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
3. China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network
4. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
5. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
6. VWR International, LLC Acquires Jencons (Scientific) Ltd, UK
7. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
8. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
9. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
10. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
11. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 Capricor Therapeutics, ... focused on the discovery, development and commercialization of first-in-class ... Chief Executive Officer, is scheduled to present at the ... at 10:50 a.m. EST, at The Lotte New York ... . . --> ...
(Date:11/24/2015)... , Nov. 24, 2015  PDL BioPharma, Inc. (PDL) ... McLaughlin , the company,s president and chief executive officer, will ... Conference next week in New York City ... on Tuesday, December 1, 2015 at 9:30 a.m. EST. ... connect to the website at least 15 minutes prior to ...
(Date:11/24/2015)... ... November 24, 2015 , ... Whitehouse Laboratories is pleased ... The new stand-alone facility will be strictly dedicated to basic USP 61, USP 62 ... clients the chance to have complete chemistry and micro testing performed by one supplier. ...
(Date:11/23/2015)... , Nov. 24, 2015 Women with a certain ... exams face a higher risk of lung cancer than men ... next week at the annual meeting of the Radiological Society ... --> --> Lung nodules are ... as solid or subsolid based on their appearance on CT. ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
Breaking Biology News(10 mins):